TJ Talks

Caught between enthusiasm for technical innovation and the need for a critical assessment of research practices, the oncology is seeking a new path that offers real hope for effective treatments and a fair distribution of resources for the benefit of patients, because, as Prof. Gyawali’s elderly patient suggests, the real issue is that the quality of life depends entirely on the patient's perspective, which should not be ignored. Enjoy listening to this episode of TJ Talks: a passionate reflection on the therapeutic approach, the balance between the acceleration of innovation and what has been proven to work, and the urgent need for a common-sense revolution in oncology. Prof. Bishal Gyawali is medical oncology and professor at Queen's University, (Canada) and, together with Dr Dario Trapani (medical oncologist at the IEO, Milan, Italy) - who is hosting the podcast on this occasion - is one of the founders of the Common Sense Oncology Movement, launched in 2023.See omnystudio.com/listener for privacy information.

Imparare a governare l'innovazione: questo l'invito che il cosiddetto Common Sense Oncology rivolge alla comunità oncologica per un approccio terapeutico interamente centrato sui bisogni del paziente. Alla base del ragionamento c'è una domanda semplice: siamo sicuri che più trattamento significhi sempre migliore medicina? E per comprendere cosa comporti trasformare questo principio in politica clinica nel contesto italiano, il dr. Dario Trapani ha incontrato per TJ Talks il prof. Massimo Di Maio, Presidente AIOM, e il dr. Francesco Perrone, Presidente della Fondazione AIOM, impegnati da tempo a portare il Common Sense Oncology dal piano del dibattito a quello dell'azione.See omnystudio.com/listener for privacy information.

From advances in the screening of prostate cancer to the management of the genitourinary tumors, the GU oncology addresses ever more clinical challenges.  What are the most relevant challenges in the management of the prostate cancer population? "It is crucial to balance the right treatment strategy with the right endpoint for patients": Professor Silke Gillessen gets straight to the point of the question posed by Dr Giuseppe Procopio, Head of the Department of Genitourinary Medical Oncology Unit at IRCCS National Cancer Institute Milan, and Editor of the GU Section of the Tumori Journal. The guest expert of this TJ Talks podcast is Silke Gillessen, Medical and Scientific Director of the Oncology Institute of Southern Switzerland and Full Professor at University of Italian Switzerland, focusing her research in genitourinary areas. In terms of endpoints - she continues - overall survival is the gold endpoint. But when it comes to metastatic prostate cancer, it is necessary to aim for a mix of quality of life, which is very important, and oncological outcomes. These should include improvements related to patients' quality of life, such as time to progression and time to symptomatic events. Patients remind us that we must think not only about the disease, but also about their well-being. Learn more about the genitourinary cancer care scenario from one of the leading voices in the field. Enjoy your listening!See omnystudio.com/listener for privacy information.

The choice of an endpoint can really change the way a treatment is administered or approved for use on patients. And in the future, we will see much more data on quality of life, and trials will probably also work on validating surrogate endpoints and biomarkers.  In this TJ Talks dedicated to the hot topic of endpoints in clinical trials, Gabriele Zoppoli, Associate Professor of Medicine at University of Genoa and Internal Medicine Consultant at Policlinico San Martino (Genoa) meet Erman Akkus, MD at Ankara University, Faculty of Medicine, Department of Medical Oncology. Alongside “primary clinical endpoints”, which concern overall survival and quality of life, surrogate endpoints are early or indirect measures of these primary endpoints, such as progression-free survival and response rate. Their purpose? To facilitate clinical trials and drug approval, but surrogate endpoints are still an active area of research and are the subject of debate in oncology. Meanwhile, patients' perceptions are waiting to be taken more seriously. Get insights, listen to the TJ Talks podcastSee omnystudio.com/listener for privacy information.

Pharmaco-prevention of breast cancer is an evidence-based strategy that uses drugs to reduce the risk of disease in high-risk women. However, the use of this strategy remains modest due to concerns about toxicity, low awareness and difficulties in patient selection. In this TJ Talks podcast, together with Prof. Andrea De Censi, director of the Breast Unit at the Champalimaud Foundation in Lisbon, Portugal, here in conversation with Prof. Antonino Musolino (director of the Medical Oncology Unit at the IRCCS-Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Forlì-Cesena), we will examine what practical solutions can bridge the gap between pharmacological prevention, indication and adoption, with a look at the future perspectives in this setting. Enjoy your listening!See omnystudio.com/listener for privacy information.

Stories of foreign cancer patients who ask to return to their country at the end of their lives: their deep desire to see their loved ones one last time is intertwined with medical, legal and financial issues that seem insurmountable. In this TJ Talks, Dr Sergio Defendi, director of Palliative Care and Home Care at Asst Crema, who has been providing assistance with end-of-life travel for years, discusses this issue together with Dr Luca Zambelli, from the Palliative Care Unit of the IRCCS National Cancer Institute Foundation in Milan. How should the responsibility for end-of-life repatriation be managed? Clinical uncertainty, the legal issue of the use of certain drugs, and the protection of patients and accompanying doctors should be addressed in guidelines or care pathways that deal with this sensitive issue. This is the next challenge for the oncology community. Enjoy your listening!See omnystudio.com/listener for privacy information.

Storie di pazienti oncologici stranieri che chiedono di tornare nel loro Paese per il fine vita: attorno al desiderio profondo di rivedere ancora una volta i propri cari si intrecciano questioni mediche, legali, finanziarie che sembrano insormontabili. A parlarne in questo episodio di TJ Talks è il dr. Sergio Defendi, direttore S.C. Cure Palliative e Adi di Asst Crema, che da anni si occupa di dare assistenza nei viaggi per il fine vita, insieme al dr. Luca Zambelli, dell’Unità Cure Palliative Fondazione IRCCS Istituto Nazionale dei Tumori di Milano.   Come gestire la responsabilità di un rimpatrio per il fine vita? L'incertezza clinica, la questione legale dell'uso di alcuni farmaci e la tutela dei pazienti e dei medici che li accompagnano dovrebbero trovare spazio in linee guida o percorsi di cura che affrontino questo delicato problema, destinato a crescere. Una prossima sfida per la comunità oncologica. Buon ascolto!See omnystudio.com/listener for privacy information.

Looking forward to the future, the trends and challenges regarding the increasing utilization of real-world data and single-arm trials in the oncology drug approval pathway by European Medicines Agency (EMA) is very important, especially in the context of personalized medicine that will become the future. Dr. Francesco Pignatti, Scientific advisor for Oncology in the Human Medicine Division of the European Medicines Agency, is the guest of this TJ Talks episode - led by dr. Luca Moscetti, Adjunct Professor in Oncology at the Residency Program in Oncology at the University of Modena Reggio Emilia - that addresses the relevant question for cancer patients about the EMA’s position on the use of real-world data in drug approvals. It emerged during the thick TJ Talks that for big changes in the use of real-world data much will also depend on the uncertainty one is willing to accept in a specific situation. Single-arm trial, for example, comes with a lot of uncertainty, mostly about the time related endpoints like survival, then you have to you tend to accept them more where you have high unmet medical needs. The goal of the scientific community is to focus the efforts on what really matters, trying to be more efficient, cleverer and to design quality criteria that are fit for purpose and that are proportionate to the objectives. Regulators, academics and the sponsors need to facilitate this type of research, maximising the opportunities that come from its data. Enjoy the listening hereSee omnystudio.com/listener for privacy information.

Le parole del prof. Paolo Marchetti restituiscono il quadro complesso dell’oncologia di precisione con il ritmo epico delle grandi imprese di frontiera.  E’ lui - Professore Ordinario di Oncologia Medica dell’Università degli Studi di Roma “La Sapienza”, Direttore Scientifico di IDI-IRCCS, Presidente della Fondazione per la Medicina Personalizzata e promotore dello studio clinico Trial Rome  - grande esperto dell’oncologia di precisione in Italia, l’ospite di questo episodio di TJ Talks, condotto dal prof. Giancarlo Pruneri.   Un concetto ampio quello dell’oncologia di precisione, basato sullo studio del genoma delle cellule tumorali, per illustrare il quale  il prof. Marchetti sottolinea i vantaggi clinici che l’applicazione di questo percorso comporta, senza dimenticare quei fattori perturbanti la possibile risposta a un determinato farmaco: come le interazioni, le modificazioni del microbiota, stili di vita e attività fisica. Un quadro complesso che promuove il confronto tra clinici, biologi molecolari, patologi e genetisti su un numero crescente di dati eterogenei.   E l’intelligenza artificiale? Fondamentale per gestire i dati provenienti da studi clinici a livello europeo, o presenti in piattaforme nazionali; indispensabile per comprendere i potenziali meccanismi di resistenza ai farmaci e per la sintesi delle conoscenze più appropriate e personalizzate per la cura del paziente.See omnystudio.com/listener for privacy information.

In this episode of TJ Talks, the guest is Professor Paolo Marchetti, a well-known expert in precision oncology in Italy, Full Professor of Medical Oncology at the University of Rome "La Sapienza", Scientific Director of IDI-IRCCS, President of the Foundation for Personalized Medicine and promoter of the Trial of Rome clinical study. Precision oncology is a broad concept based on the study of the genome of tumour cells and Prof. Marchetti – interviewed by Prof. Giancarlo Pruneri -  highlights the clinical advantages of applying this path, without forgetting the factors that interfere with the possible response to a given drug: such factors include interactions, alterations of the microbiota, lifestyle and physical activity, making the scenario even more complex and fostering comparison among clinicians, molecular biologists, pathologists and geneticists on an ever-increasing number of heterogeneous data. In precision oncology, the role of artificial intelligence in managing data from clinical trials is essential to understand potential mechanisms of drug resistance and synthesize the most appropriate and personalized knowledge for patient care.See omnystudio.com/listener for privacy information.

If we were to stop at a first glance, the use of liquid biopsy would be limited in the clinical practice of colorectal cancer to cases where tumour tissue is unavailable or insufficient. In reality, we are at the beginning of a pathway where the true potential of liquid biopsy is developing rapidly in several directions. This is confirmed by the research results of Prof. Andrea Sartore Bianchi - Director of the Division of Clinical Research and Innovation in Medical Oncology at the Grande Ospedale Metropolitano Niguarda in Milan. One of the most promising applications of liquid biopsy is the detection of minimal residual disease, a potentially game-changing application for oncologists in the field of colorectal cancer, that guides the choice of the most appropriate treatment for patients. Find out how liquid biopsy is absolutely the new goal of precision oncology, capable of technologically and culturally revolutionising clinical practice, in this TJ Talks podcast, hosted by Prof. Giancarlo Pruneri.See omnystudio.com/listener for privacy information.

The field of bioinformatics is rapidly evolving, shaping the future of biomedical research and precision medicine. From cutting-edge advancements in computational biology to AI-driven solutions, what will the landscape look like in Italy in the coming years, and what opportunities will emerge for young bioinformaticians?In this TJ Talks event, the Bioinformatics Section Editor of Tumori Journal, Prof. Lorenzo Ferrando - Research Associate of Applied Medical Technology and Sciences, Department of Internal Medicine, University of Genoa - guides us through a discussion on the key trends and career prospects in bioinformatics. Joining him is Prof. Matteo Benelli, Associate Professor of Biochemistry at the University of Florence and Co-Principal Investigator of AURORA, an international research program dedicated to uncovering the molecular mechanisms driving therapy response and resistance in recurrent metastatic breast cancer.See omnystudio.com/listener for privacy information.

Drug resistance is a major challenge in oncology and genetically-engineered mouse models represent powerful tools to identify new approaches for its overcoming. In this TJ Talks podcast, Prof Paola Perego, Pharmacology Section Editor of Tumori Journal and Adjunct Professor at the University of Insubria, talks with Professor Sven Rottenberg, head of the Institute of Animal Pathology at the University of Bern, about drug resistance and the reasons why it is so difficult to eradicate tumors during treatment.See omnystudio.com/listener for privacy information.

Dr. Arsela Prelaj is confident: the implementation of Artificial Intelligence in Oncology, in the near future, will be aimed at advances in screening and the use of images, such as radiomics; in digital pathology, for a diagnostic task, and in applying Large Language Model for automation tasks. However, there will be climbs to overcome along the way. In this TJ Talks podcast, Dr Arsela Prelaj, Thoracic Oncologist and Director of the Artificial Intelligence for Oncology Lab at the National Cancer Institute of Milan, talks with Prof. Giancarlo Pruneri about a new world where physicians will interact with Artificial Intelligence in daily clinical practice.See omnystudio.com/listener for privacy information.

In this TJ Talks podcast, Dr Luca Agnelli, Tumori Journal Section Editor for Bioinformatics, meets Prof George Calin, a distinguished scientist with an extraordinary career dedicated to studying microRNAs, non-coding RNAs, and their impact on cancer. Listening to their exciting conversation, you will be engaged in the Prof. Calin's diverse research experiences across Eastern Europe, Western Europe, and the USA, while knowing into key topics in scientific research. These include challenges to amend the peer-review process and the pressing question of whether to focus on generating more big data or optimizing the use of existing -omics datasets. See omnystudio.com/listener for privacy information.

A scientific society for integrating all aspects of cancer care - diagnostics, pathology, surgery, radiation, and medical oncology -through a multidisciplinary approach, because the future of medical oncology will focus on understanding cancer biology and intercepting the disease before it appears or recurs.In this TJ Talks, prof. Giuseppe Curigliano, chair of the Division of Early Drug Development at the European Institute of Oncology in Milan, and professor at the University of Milan School of Medicine, talks with prof. Giancarlo Pruneri on the future of precision oncology and his commitment as President-elect of ESMO.See omnystudio.com/listener for privacy information.

Evidence suggests that dietary interventions can effectively delay, treat and even prevent certain illnesses. This leads to the hypothesis that metabolic interventions might aid cancer treatment, and this is the focus of the conversation with one of the most distinguished researchers in the field. The guest of this episode of TJ Talks, hosted by prof. Giancarlo Pruneri, is dr. Claudio Vernieri, breast oncologist at the National Cancer Institute of Milan, and PI of the Breakfast-2 study. Breakfast-2 is a very promising prospective study on the efficacy of a metabolic intervention combined to chemo-immunotherapy for patients with triple negative breast cancer.See omnystudio.com/listener for privacy information.

The role of pathologists in precision oncology is increasingly recognised as central to effective cancer diagnosis and treatment. Their expertise in tumor classification and biomarker identification is crucial for the development of personalised therapies through advanced molecular biology techniques. To explore the unique aspects of the pathology postgraduate course at University of Milan, the Editor in Chief of Tumori Journal, Prof. Giancarlo Pruneri, invited Dr. Emanuele Frigo, who is completing his PhD in Milan, and through his experiences and insights, we will discover the distinctive opportunities offered by INT's PhD programme and how it shapes the future of pathologists and physician-scientists.See omnystudio.com/listener for privacy information.

TJ Talks is an educational initiative featuring conversations about oncology led by Prof. Giancarlo Pruneri, Editor in Chief of Tumori Journal. The podcast series aims to explore a variety of topics of interest that reflect the dynamic and evolving nature of oncology research, with contributions from renowned international experts and promising young researchers in the field. Through these insightful discussions, TJ Talks seeks to support the professional development of clinicians and researchers working to improve the cancer care. TJ Talks is available on our website and on the best podcast platforms. Follow us on Twitter and LinkedIn to always be updated on cancer research and clinical practice in oncology!See omnystudio.com/listener for privacy information.